A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Cabozantinib (Primary) ; Nivolumab (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- 19 Feb 2018 Planned End Date changed from 30 Apr 2019 to 23 Jan 2021.
- 19 Feb 2018 Planned primary completion date changed from 30 Apr 2019 to 23 Jan 2021.
- 15 Feb 2018 Status changed from not yet recruiting to recruiting.